New York’s Medicaid program’s Drug Utilization Review Board pushed a 10-0 vote to lower the price the state would pay for Vertex Pharmaceuticals’ Orkambi.
The aims to drop payment for the cystic fibrosis drug to $83,000 per year, a significant reduction from $250,000.
“As a lung physician, I appreciate that Orkambi does have benefits — it eases breathing and prevents some of the acute episodes that can land cystic fibrosis patients in the hospital,” Peter Bach writes in a column published on Bloomberg. ” … But like many other states, New York is having trouble affording prescription drugs for Medicaid patients.”
To read his full commentary on Bloomberg, click here.